|Videos|June 22, 2021

Pharmacist Medication Insights: Xembify for Primary Humoral Immunodeficiency Disease

Xembify (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease in patients 2 years of age and older.

Xembify is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME

In-Person Conference

NEIAP Conference 2026

September 11, 2026

Virtual Event

PBMI 2026

September 10 - September 11, 2026

Pharmacist Medication Insights: Xembify for Primary Humoral Immunodeficiency Disease

Related Content

The Growing Role of Digital Health and Pharmacist Guidance

Tiny Parasite, Big Problem: Managing Cyclosporiasis in Pediatric Patients

When Is a Carcinogen Really a Carcinogen?

Under the Skin: What Subcutaneous Isatuximab Means for Myeloma Care

FDA Approves Garetosmab-grts, First Treatment for FOP Bone Growth

Latest CME

NEIAP Conference 2026

PBMI 2026

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Advancing the Idiopathic Pulmonary Fibrosis Treatment Landscape: What’s Next in Care

Biomarker Testing in Practice: Navigating Modalities and Multidisciplinary Decision-Making

The Educated Pharmacist: Overcoming Clinical Inertia—An Interactive Case Workshop for Optimizing Insulin Use

Two Targets, One Mission: Optimizing Bispecific Antibody Use in Non-Hodgkin Lymphoma

Navigating the Complexities of Personalized Prostate Cancer Care: Insights for Oncology Managed Care

Navigating Outpatient Bispecific Antibody Administration in Lymphoma: Practical Solutions for Community Oncology Practices

Opioids, Pain Management, and Substance Use Disorder: A Practical Overview

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Paroxysmal Nocturnal Hemoglobinuria: Managed Care Strategies to Mitigate Burden and Enhance Outcomes

Infectious Disease Day of Education 2026

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

Looking at Patient-Centered Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Through a Value-Based Lens

Lymphoma Day of Education 2026

Shingles Vaccination: Opportunities for Pharmacist Interventions to Provide Patient Education

Evolving Care in IgA Nephropathy: Translating Emerging Evidence Into Care

Advancing HER2-Driven Cancer Care, Biomarker Testing, and Pharmacist Innovation

NEIAP 2026 Annual Forum

Exploring Oncolytic Viruses in Melanoma: Pharmacist-Led Approaches for Safe Integration

Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia With Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

Minimizing Injection Burden: Anti-VEGF Innovation for Retinal Disease Management

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Managing Steroid-Refractory Chronic Graft-versus-Host Disease With Novel Therapies: Opportunities for Pharmacist-Led Interventions

New Oncology Therapy Approvals for 2025 (Pharmacist Credit)

Lymphoma Day of Education 2026

The Pharmacist's Role in Palliative and End of Life Symptom Management

Reducing the Treatment Burden in HIV Management: The Pharmacist’s Role in Long-Acting Injectable Adoption

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

Targeting the Complement Cascade: Evolving Strategies in the Management of Complement-Mediated Kidney Diseases

New Oncology Therapy Approvals for 2025 (Pharmacy Technician Credit)

Redefining Care in Polycythemia Vera and Essential Thrombocythemia: Emerging Evidence, Evolving Strategies, and the Pharmacist’s Role

The Educated Pharmacist - Weighing In: Translating Evidence to Practice — A Multidisciplinary Analysis of Obesity Pharmacotherapy Implementation and Team-Based Care

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Advancing the Management of Hidradenitis Suppurativa: Emerging Therapies and Managed Care Strategies Across Patient Populations

Improving Outcomes in Fibrosing Interstitial Lung Diseases: Exploring Novel Mechanisms of Action and New Indications to Inform Clinical and Managed Care Decision-Making

Innovations in Narcolepsy Treatment: Emerging Targets and Implications for Managed Care

Evolving Treatment Options in Plaque Psoriasis: Implications of Emerging TYK2 Inhibitors for Managed Care

New Treatments in Systemic Lupus Erythematosus to Advance Care: A Managed Care Focus on Nephritis

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Infectious Disease Day of Education 2026

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

Optimizing Antibody-Drug Conjugate Safety: Pharmacist Strategies for Grading, Monitoring, and Supportive Care

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians (Pharmacy Technician Credit)

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Optimizing Lipid Management in Statin-Intolerant Populations: Payer Strategies for Evidence-Based Access and Risk Reduction

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

From Guidelines to Action: Implementing Pneumococcal Vaccine ACIP Recommendations in Long-Term Care Settings

Influenza Immunization in Older Adults: Enhanced Vaccines and Best Practices for Long-Term Care Pharmacists

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

New Horizons in ATTR-CM: Therapeutic Advances and Strategic Insights

Innovations in Retinal Therapies: A Managed Care Perspective on Anti-VEGF Advancements

Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care